Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

Nature Medicine

Volumn 23, Issue 8, 2017, Pages 990-996

  Benoit, Bérengère ^a   Meugnier, Emmanuelle ^b   Castelli, Martina ^a   Chanon, Stéphanie ^b   Vieille Marchiset, Aurélie ^b   Durand, Christine ^b   Bendridi, Nadia ^b   Pesenti, Sandra ^b   Monternier, Pierre Axel ^b   Durieux, Anne Cécile ^c   Freyssenet, Damien ^c   Rieusset, Jennifer ^b   Lefai, Etienne ^b   Vidal, Hubert ^b   Ruzzin, Jérôme ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITÉ DE LYON   (France)

^c Univ Lyon University Jean Monnet Saint Etienne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 21; KLOTHO BETA PROTEIN; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT FIBROBLAST GROWTH FACTOR 19; S6 KINASE; UNCLASSIFIED DRUG; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GLUCOCORTICOID; KLB PROTEIN, MOUSE; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; TRANSCRIPTOME;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GRIP STRENGTH; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE STRENGTH; MYOTUBE; NONHUMAN; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; SARCOPENIA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SKELETAL MUSCLE CELL; ANIMAL; DRUG EFFECTS; GENETICS; HAND STRENGTH; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; METABOLISM; ORGAN SIZE; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL SIZE; FIBROBLAST GROWTH FACTORS; GLUCOCORTICOIDS; HAND STRENGTH; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO TECHNIQUES; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; OBESITY; ORGAN SIZE; RECOMBINANT PROTEINS; SARCOPENIA; TRANSCRIPTOME;

EID: 85026521591     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4363     Document Type: Article

References (36)

1. Degirolamo, C., Sabbà, C., Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51-69 (2016).
2. Lin, B.C., Wang, M., Blackmore, C., Desnoyers, L.R. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282, 27277-27284 (2007).
3. Owen, B.M., Mangelsdorf, D.J., Kliewer, S.A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26, 22-29 (2015).
4. Ornitz, D.M., Itoh, N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215-266 (2015).
5. Kir, S., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624 (2011).
6. Inagaki, T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225 (2005).
7. Adams, A.C., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31-37 (2013).
8. Fu, L., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594-2603 (2004).
9. Kurosu, H., et al. Tissue-specific expression of Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695 (2007).
10. Tomlinson, E., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143, 1741-1747 (2002).
11. Morton, G.J., et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799-4808 (2013).
12. Miyata, M., Sakaida, Y., Matsuzawa, H., Yoshinari, K., Yamazoe, Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol. Pharm. Bull. 34, 1885-1889 (2011).
13. Baskin, K.K., Winders, B.R., Olson, E.N. Muscle as a "mediator" of systemic metabolism. Cell Metab. 21, 237-248 (2015).
14. Potthoff, M.J., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1 pathway. Cell Metab. 13, 729-738 (2011).
15. Rowe, R.W., Goldspink, G. Muscle fibre growth in five different muscles in both sexes of mice. J. Anat. 104, 519-530 (1969).
16. Mashili, F.L., et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: Implications for type 2 diabetes and obesity. Diabetes Metab. Res. Rev. 27, 286-297 (2011).
17. Bodine, S.C., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014-1019 (2001).
18. Ohanna, M., et al. Atrophy of S6K1-/-skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7, 286-294 (2005).
19. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P., Blenis, J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101, 13489-13494 (2004).
20. Nicole, S., et al. Intact satellite cells lead to remarkable protection against Smn gene defect in differentiated skeletal muscle. J. Cell Biol. 161, 571-582 (2003).
21. Anker, S.D., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050-1053 (1997).
22. Kim, T.N., et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 33, 1497-1499 (2010).
23. Wada, S., et al. Translational suppression of atrophic regulators by microRNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. 286, 38456-38465 (2011).
24. Gilson, H., et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148, 452-460 (2007).
25. Kammoun, M., Cassar-Malek, I., Meunier, B., Picard, B. A simplified immunohistochemical classification of skeletal muscle fibres in mouse. Eur. J. Histochem. 58, 2254 (2014).
26. Sawey, E.T., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347-358 (2011).
27. Zhou, M., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 74, 3306-3316 (2014).
28. Ding, X., et al. Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387-393 (2012).
29. Miniou, P., et al. Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res. 27, e27 (1999).
30. Pasut, A., Jones, A.E., Rudnicki, M.A. Isolation and culture of individual myofibers and their satellite cells from adult skeletal muscle. J. Vis. Exp. 73, e50074 (2013).
31. Cozzone, D., et al. Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 49, 990-999 (2006).
32. Rieusset, J., et al. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53, 2232-2241 (2004).
33. Dessalle, K., et al. SREBP-1 transcription factors regulate skeletal muscle cell size by controlling protein synthesis through myogenic regulatory factors. PLoS One 7, e50878 (2012).
34. De Larichaudy, J., et al. TNF-A nd tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet. Muscle 2, 2 (2012).
35. Ruzzin, J., et al. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ. Health Perspect. 118, 465-471 (2010).
36. Bravard, A., et al. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. Diabetes 60, 258-268 (2011).